The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome

DOI: 10.1093/infdis/jit554
Journal of Infectious Diseases, 2014, 209, 1343-53.

#	Paper	IF	Citations
34	Avian influenza A H7N9 virus induces severe pneumonia in mice without prior adaptation and responds to a combination of zanamivir and COX-2 inhibitor. *PLoS ONE*, **2014**, 9, e107966	3.7	32
33	Safety and efficacy of peramivir for influenza treatment. *Drug Design, Development and Therapy*, **2014**, 8, 2017-38	4.4	19
32	An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality. *Journal of Infectious Diseases*, **2014**, 210, 435-40	7	41
31	TMPRSS2 is a host factor that is essential for pneumotropism and pathogenicity of H7N9 influenza A virus in mice. *Journal of Virology*, **2014**, 88, 4744-51	6.6	100
30	Human H7N9 and H5N1 influenza viruses differ in induction of cytokines and tissue tropism. *Journal of Virology*, **2014**, 88, 12982-91	6.6	29
29	H7N9 and other pathogenic avian influenza viruses elicit a three-pronged transcriptomic signature that is reminiscent of 1918 influenza virus and is associated with lethal outcome in mice. *Journal of Virology*, **2014**, 88, 10556-68	6.6	37
28	Mammalian models for the study of H7 virus pathogenesis and transmission. *Current Topics in Microbiology and Immunology*, **2014**, 385, 275-305	3.3	16
27	[Progress in Diagnostic Technology and Management of Infectious Diseases. Topics: I. Infectious Diseases with Special Concern; 4. Emerging infectious diseases in recent years]. *The Journal of the Japanese Society of Internal Medicine*, **2014**, 103, 2680-7	0	
26	The Tie2-agonist Vasculotide rescues mice from influenza virus infection. *Scientific Reports*, **2015**, 5, 11030	4.9	41
25	Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 7255-64	5.9	6
24	Sialic acid-binding protein Sp2CBMTD protects mice against lethal challenge with emerging influenza A (H7N9) virus. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1495-504	5.9	8
23	Influenza A(H7N9) virus acquires resistance-related neuraminidase I222T substitution when infected mallards are exposed to low levels of oseltamivir in water. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 5196-202	5.9	18
22	Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 4962-73	5.9	34
21	Influenza A(H7N9) virus transmission between finches and poultry. *Emerging Infectious Diseases*, **2015**, 21, 619-28	10.2	16
20	Combinations of oseltamivir and fibrates prolong the mean survival time of mice infected with the lethal H7N9 influenza virus. *Journal of General Virology*, **2015**, 96, 46-51	4.9	9
19	A Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo Protection from Influenza Independent of a Host Immune Response. *PLoS Pathogens*, **2016**, 12, e1005409	7.6	36
18	Translational research on influenza virus infection using a nonhuman primate model. *Pathology International*, **2016**, 66, 132-141	1.8	7

17	Reduction of Neuraminidase Activity Exacerbates Disease in 2009 Pandemic Influenza Virus-Infected Mice. *Journal of Virology*, **2016**, 90, 9931-9941	6.6	4
16	The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 2118-31	5.9	38
15	Vascular Permeability Drives Susceptibility to Influenza Infection in a Murine Model of Sickle Cell Disease. *Scientific Reports*, **2017**, 7, 43308	4.9	6
14	The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo. *Antiviral Research*, **2017**, 142, 178-184	10.8	36
13	Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses. *Antiviral Research*, **2017**, 142, 12-15	10.8	4
12	Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques. *Journal of Infectious Diseases*, **2017**, 216, 582-593	7	13
11	Pharmacodynamics, Pharmacokinetics, and Antiviral Activity of BAY 81-8781, a Novel NF-B Inhibiting Anti-influenza Drug. *Frontiers in Microbiology*, **2017**, 8, 2130	5.7	15
10	Anti-influenza effect of the major flavonoids from Salvia plebeia R.Br. via inhibition of influenza H1N1 virus neuraminidase. *Natural Product Research*, **2018**, 32, 1224-1228	2.3	19
9	The Antihistamine Drugs Carbinoxamine Maleate and Chlorpheniramine Maleate Exhibit Potent Antiviral Activity Against a Broad Spectrum of Influenza Viruses. *Frontiers in Microbiology*, **2018**, 9, 2643	5.7	18
8	Zoonotic Influenza and Human Health-Part 2: Clinical Features, Diagnosis, Treatment, and Prevention Strategies. *Current Infectious Disease Reports*, **2018**, 20, 38	3.9	2
7	Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil. *Scientific Reports*, **2019**, 9, 3466	4.9	19
6	A77 1726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases. *FASEB Journal*, **2020**, 34, 10132-10145	0.9	6
5	Low replicative fitness of neuraminidase inhibitor-resistant H7N9 avian influenza a virus with R292K substitution in neuraminidase in cynomolgus macaques compared with I222T substitution. *Antiviral Research*, **2020**, 178, 104790	10.8	2
4	Substitution of I222L-E119V in neuraminidase from highly pathogenic avian influenza H7N9 virus exhibited synergistic resistance effect to oseltamivir in mice. *Scientific Reports*, **2021**, 11, 16293	4.9	1
3	Ex Vivo Validation of Six FDA-Approved Non-Receptor Tyrosine Kinase Inhibitors (NRTKIs) as Antivirals to Pandemic and Seasonal Influenza A Viruses.		0
2	Data_Sheet_1.docx. **2018**,		
1	FDA-approved Abl/EGFR/PDGFR kinase inhibitors show potent efficacy against pandemic and seasonal influenza A virus infections of human lung explants. **2023**, 26, 106309		0